{"nctId":"NCT02137850","briefTitle":"Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A","startDateStruct":{"date":"2014-06-26","type":"ACTUAL"},"conditions":["Congenital Bleeding Disorder","Haemophilia A"],"count":124,"armGroups":[{"label":"50 EDs (exposure days)","type":"EXPERIMENTAL","interventionNames":["Drug: turoctocog alfa pegol"]}],"interventions":[{"name":"turoctocog alfa pegol","otherNames":["NNC 0129-0000-1003","N8-GP"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial\n* Male, age below 6 years of age at the time of signing informed consent\n* Diagnosis of severe haemophilia A (FVIII activity level 1%) based on medical records or central laboratory results\n* No prior use of purified clotting factor products (5 previous exposures to blood components is acceptable)\n\nExclusion Criteria:\n\n* Any history of FVIII inhibitor (defined by medical records) - Known or suspected hypersensitivity to trial product or related products\n* Previous participation in this trial. Participation is defined as first dose administered of trial product\n* Receipt of any investigational medicinal product within 30 days before screening\n* Congenital or acquired coagulation disorder other than haemophilia A\n* Any chronic disorder or severe disease which, in the opinion of the Investigator, might jeopardise the patient's safety or compliance with the protocol\n* Patient's parent(s')/legally acceptable representative (LAR(s')) mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation","healthyVolunteers":false,"sex":"MALE","minimumAge":"0 Years","maximumAge":"6 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII (FVIII)","description":"Number of participants with inhibitory antibodies against coagulation factor VIII (FVIII) was reported during the main and extension phase of the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events Including Serious Adverse Events and Medical Events of Special Interest","description":"Number of adverse events including serious adverse events and medical events of special interest reported during the main and extension phase of the trial. An adverse event (AE) is any untoward medical occurrence in a patient administered a product, and which does not necessarily have a causal relationship with this treatment. Serious adverse event (SAE) is an experience that at any dose results in any of the following: Death, a life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect and important medical events that may not result in death, be life threatening or require hospitalisation. Medical event of special interest (MESI) is an event which, in the evaluation of safety, has a special focus.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"644","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Confirmed High Titre Inhibitors (Defined as Inhibitor Titre Above 5 Bethesda Units (BU)","description":"Number of participants with confirmed high titre inhibitors (defined as inhibitor titre above 5 Bethesda Units (BU) was reported during the main and extension phase of the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Breakthrough Bleeding Episodes During Prophylaxis With N8-GP (Annualised Bleeding Rate)","description":"The number of bleeding episodes per year reported during the prophylactic treatment with N8-GP was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":null}]}]}]},{"type":"SECONDARY","title":"Haemostatic Effect of N8-GP in Treatment of Bleeding Episodes, Assessed by a Predefined 4-point Haemostatic Response Scale (\"Excellent\", \"Good\", \"Moderate\" and \"None\")","description":"Haemostatic effect of turoctocog alfa pegol for treatment of bleeding episodes was assessed by 4-point response scale: none, moderate, good or excellent. Excellent: Abrupt pain relief and/or clear improvement in objective signs of bleeding within approximately 8 hours after a single injection; Good: Definite pain relief and/or improvement in signs of bleeding within approximately 8 hours after a single injection, but possibly requiring more than one injection for complete resolution; Moderate: Probable or slight beneficial effect within approximately 8 hours after the first injection, but usually requiring more than one injection; None: No improvement, or worsening of symptoms. Number of bleeding episodes in each category is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"227","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Consumption of N8-GP for Prophylaxis (International Unit Per Kilogram (IU/Kg))","description":"Consumption of N8-GP for prophylaxis is reported. Consumption used for treatment includes all doses given. Yearly consumption is only calculated for patients with a exposure time of at least 30 days. Average dose consumption in IU/kg during main and extension phase is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9","spread":"7.6"}]}]}]},{"type":"SECONDARY","title":"Consumption of N8-GP for Prophylaxis (Number of Injections)","description":"Consumption of N8-GP for prophylaxis is reported. Consumption used for treatment includes all doses given. Yearly consumption is only calculated for patients with a exposure time of at least 30 days. Number of injections consumption per patient during main and extension phase is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"236.6","spread":"208.2"}]}]}]},{"type":"SECONDARY","title":"Consumption of N8-GP for Treatment of Bleeding Episodes (International Unit Per Kilogram Per Bleed (IU/kg/Bleed))","description":"Consumption of N8-GP for treatment of bleeding episodes (IU/kg/bleed) is reported. Average dose consumption in IU/kg/bleed during main and extension phase is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112.9","spread":"113.4"},{"groupId":"OG001","value":"92.1","spread":"71.7"}]}]}]},{"type":"SECONDARY","title":"Consumption of N8-GP for Treatment of Bleeding Episodes (Number of Injections)","description":"Consumption of N8-GP for treatment of bleeding episodes (number of injections) is reported. Number of average injections required for treatment of per bleed is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.6"},{"groupId":"OG001","value":"1.3","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Total Consumption of N8-GP Per Patient (Prevention and Treatment of Bleeding Episodes) Annualised Value","description":"Total consumption of N8-GP per patient (prevention and treatment of bleeding episodes) annualised value is presented. Consumption used for treatment includes all doses given. Yearly consumption is only calculated for patients with a exposure time of at least 30 days. Consumption used for treatment per year per patient (IU/kg/year/patient) is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2108.6","spread":"2697.6"},{"groupId":"OG001","value":"5394.9","spread":"1887.9"}]}]}]},{"type":"SECONDARY","title":"Outcome of ITI, Assessed by a Predefined 4-point ITI Outcome Scale (\"Success\", \"Partial Success\", \"Failure\", \"Other\")","description":"The outcome of ITI was evaluated by predefined 4-point outcome of ITI scale ('success', 'partial success', 'failure', 'other'). Success: An inhibitor titre less than (\\<) 0.6 BU. A normalised FVIII recovery, defined as greater than or equal to (≥) 66 percentage (%) of expected incremental recovery. An N8-GP half-life (t½) ≥9 hours after a 72-hour treatment-free washout period. Partial success: Reduction in inhibitor titre to less than or equal to (≤) 5 BU. Clinical effect of N8-GP therapy as judged by the investigator. Failure: Failure to attain defined success or partial success within 24 months of uninterrupted ITI with N8-GP. Inhibitor decrease less than (\\<) 20% after one year of ITI treatment. Other: Not fulfilling the above criteria. Number of participants in each category is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":55},"commonTop":["Pyrexia","Nasopharyngitis","Upper respiratory tract infection","Cough","Ear infection"]}}}